TY - JOUR
T1 - Results of combined therapy for maxillary sinus squamous cell carcinoma
AU - Shoko, Yamada
AU - Shu, Onodera
AU - Katsuya, Yahara
AU - Takayuki, Ohguri
AU - Fumio, Kato
AU - Satoshi, Nomoto
AU - Hajime, Imada
AU - Hajime, Nakata
AU - Hiromi, Terashima
AU - Koji, Kudoh
AU - Masafumi, Yoshida
PY - 2003/7/25
Y1 - 2003/7/25
N2 - The results of 54 cases of maxillary sinus squamous cell carcinoma treated between 1980 and 2002 were analyzed retrospectively. The T classification according to the 1997 UICC was as follows: 2 with stage T1, 29 with T3, and 23 with T4. Ten patients (18.5 %) had lymph node metastases at diagnosis. All patients underwent combined therapy including radiotherapy surgery, and regional or systemic chemotherapy. Fifteen patients received hyperfractionated twice-daily radiotherapy (1.2 Gy or 1.5 Gy/fraction), and the remaining 39 patients received a conventional once-daily regimen (1.5-2 Gy/fraction). The 5-year overall survival and 5-year disease-free survival for all patients were 56.0% and 46.7%, respectively. The N classification was the only significant prognostic factor for 5-year disease-free survival by univariate analysis (favoring N=0, p=0.04). There were no significant differences in other prognostic factors including gender, T classification (T1-3 vs. T4), hyperfractionated radiotherapy (yes vs. no), total dose (BED: <69 Gy 10 vs. ≧69 Gy10), and intra-arterial chemotherapy (yes vs. no). Although radiation-induced cataract was observed in 9 patients, no other severe late complications developed.
AB - The results of 54 cases of maxillary sinus squamous cell carcinoma treated between 1980 and 2002 were analyzed retrospectively. The T classification according to the 1997 UICC was as follows: 2 with stage T1, 29 with T3, and 23 with T4. Ten patients (18.5 %) had lymph node metastases at diagnosis. All patients underwent combined therapy including radiotherapy surgery, and regional or systemic chemotherapy. Fifteen patients received hyperfractionated twice-daily radiotherapy (1.2 Gy or 1.5 Gy/fraction), and the remaining 39 patients received a conventional once-daily regimen (1.5-2 Gy/fraction). The 5-year overall survival and 5-year disease-free survival for all patients were 56.0% and 46.7%, respectively. The N classification was the only significant prognostic factor for 5-year disease-free survival by univariate analysis (favoring N=0, p=0.04). There were no significant differences in other prognostic factors including gender, T classification (T1-3 vs. T4), hyperfractionated radiotherapy (yes vs. no), total dose (BED: <69 Gy 10 vs. ≧69 Gy10), and intra-arterial chemotherapy (yes vs. no). Although radiation-induced cataract was observed in 9 patients, no other severe late complications developed.
UR - http://www.scopus.com/inward/record.url?scp=0141834166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141834166&partnerID=8YFLogxK
M3 - Article
C2 - 12934550
AN - SCOPUS:0141834166
SN - 0048-0428
VL - 63
SP - 316
EP - 321
JO - Nippon Acta Radiologica
JF - Nippon Acta Radiologica
IS - 6
ER -